Published in Biochem Pharmacol on February 01, 1970
The characterization of two reduced nicotinamide-adenine dinucleotide phosphate-linked aldehyde reductases from pig brain. Biochem J (1972) 1.06
Simulation of biogenic amine metabolism in the brain. Biochem J (1974) 0.98
Determination and significance of l-tyrosine O-sulphate and its deaminated metabolites in normal human and mouse urine. Biochem J (1973) 0.86
Brain concentrations of biogenic amine metabolites in acutely treated and ethanol-dependent rats. Br J Pharmacol (1976) 0.75
A fluorimetric study of the hydroxylation of biphenyl in vitro by liver preparations of various species. Biochem J (1965) 2.47
A spectrofluorimetric study of the 7-hydroxylation of coumarin by liver microsomes. Biochem J (1965) 1.76
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol (1998) 1.72
The fluorescence of some biphenyl derivatives. Biochem J (1965) 1.47
In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res (1993) 1.37
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep (1972) 1.32
Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep (1977) 1.29
Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res (1982) 1.14
Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol Biomarkers Prev (1995) 1.12
The stimulation of hydroxylation by carcinogenic and non-carcinogenic compounds. Biochem Pharmacol (1966) 1.09
Metabolism of tyramine-1-14C by the rat. Biochem Pharmacol (1970) 1.09
Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood (1979) 1.03
Ethanol oxidation in the microsomal fraction of rat liver. Biochem Biophys Res Commun (1969) 1.02
Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat Rep (1976) 0.98
Growth of cell colonies in soft agar from biopsies of different human solid tumors. Cancer Res (1980) 0.98
Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724). Cancer Treat Rep (1976) 0.98
Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett (1995) 0.96
Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res (1993) 0.96
Pharmacokinetics of divided-dose ifosfamide. Clin Pharmacol Ther (1976) 0.96
Colony growth in soft agar of human melanoma, sarcoma, and lung carcinoma cells disaggregated by mechanical and enzymatic methods. Cancer Res (1980) 0.96
Characterization of cells obtained by mechanical and enzymatic means from human melanoma, sarcoma, and lung tumors. Cancer Res (1981) 0.95
Marihuana: importance of the route of administration. J Pharm Pharmacol (1971) 0.95
Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res (1984) 0.95
Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett (1996) 0.94
Distribution of tritiated-1 delta 9tetrahydrocannabinol in rat tissues after inhalation. J Pharm Pharmacol (1970) 0.92
Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP). Cancer Treat Rep (1983) 0.91
Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol (1988) 0.91
The clinical pharmacology of VM26 and VP16-213. A brief overview. Cancer Chemother Pharmacol (1982) 0.91
Antibacterial properties of eight dental cements. Int Endod J (1993) 0.90
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep (1972) 0.89
Preliminary observations on the metabolism of (1- 14 C)tyramine in man. J Pharm Pharmacol (1972) 0.88
Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res (1996) 0.87
The effect of butylated hydroxytoluene, butylated hydroxyanisole and octyl gallate upon liver weight and biphenyl 4-hydroxylase activity in the rat. J Pharm Pharmacol (1966) 0.87
Expression of intercellular adhesion molecule-1 (ICAM-1) on human thyroid cells lines correlated with their binding of lymphoblasts. Mol Cell Endocrinol (1990) 0.87
The effect of chloral hydrate on the metabolism of ethanol in mice. J Pharm Pharmacol (1969) 0.86
Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans. Cancer Res (1988) 0.86
DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II). Cancer Chemother Pharmacol (1990) 0.86
Dealkylation of alkoxybiphenyls by trout and frog liver preparations. Life Sci (1967) 0.86
Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives. Eur J Cancer (1975) 0.85
Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res (1997) 0.85
Amphetamine analogs. II. Methylated phenethylamines. J Med Chem (1970) 0.84
A micro-method for the determination of acetaldehyde and ethanol in blood. Clin Chim Acta (1968) 0.84
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol (1996) 0.84
Metabolism of harmaline in rats. Biochem Pharmacol (1971) 0.84
Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr (1987) 0.84
Estrus cycle in rats: the role of serotonin and norepinephrine. Life Sci (1968) 0.83
Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother Pharmacol (1995) 0.83
Pharmacokinetics of ifosfamide. Clin Pharmacol Ther (1975) 0.83
Hydroxyindole-O-methyltransferase. II. Inhibitory activities of some N-acyltryptamines. J Pharm Sci (1968) 0.83
Marijuana: some pharmacological studies. J Pharm Sci (1971) 0.83
Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Semin Oncol (1995) 0.83
Effect of microsomal activation on interaction between isophosphamide and DNA. J Pharm Sci (1972) 0.82
Methotrexate in liver and bile after intravenous dosage in man. Br J Cancer (1973) 0.82
Inhibitors of monoamine oxidase. Influence of methyl substitution on the inhibitory activity of beta-carbolines. J Pharm Sci (1968) 0.82
S-phase modulation by irinotecan: pilot studies in advanced solid tumors. Cancer Chemother Pharmacol (2005) 0.82
The effect of carcinogenic and noncarcinogenic compounds on the O-dealkylating activity of the hepatic microsomal enzyme system of the rat. Biochem Pharmacol (1967) 0.82
The clinical toxicity of anticancer drugs and its prediction. Semin Oncol (1977) 0.81
Clinical pharmacology of isophosphamide. Clin Pharmacol Ther (1974) 0.81
Uptake and metabolism of iproplatin in murine L1210 cells. Cancer Chemother Pharmacol (1989) 0.80
Placental transfer of tritiated-1-delta-9-tetrhydrocannabinol. N Engl J Med (1969) 0.80
Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chemother Rep (1975) 0.80
Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity. Cancer Epidemiol Biomarkers Prev (2001) 0.80
Effect of tranylcypromine sulphate on the metabolism of ( 14 C)tyramine in vivo in the rat. J Pharm Pharmacol (1972) 0.80
Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma. Cancer (1982) 0.80
Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma. Cancer Chemother Rep (1976) 0.79
Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP). Br J Clin Pharmacol (1989) 0.79
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. Am J Clin Oncol (1998) 0.79
Activation of the antineoplastic drug isophosphamide by rat liver microsomes. J Pharm Pharmacol (1972) 0.79
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. Clin Cancer Res (2000) 0.78
In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes. Cancer Chemother Rep (1972) 0.78
Phase I clinical trial of a single-dose and two weekly schedules of ICRF-159 (NSC-129943). Cancer Chemother Rep (1974) 0.78
Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma. Cancer Chemother Pharmacol (1989) 0.78
Placental transfer and tissue distribution of ethanol-1- 14 C. A radioautographic study in monkeys and hamsters. Q J Stud Alcohol (1972) 0.78
[3H]harmaline distribution in monkey brain; pharmacological and autoradiographic study. Brain Res (1970) 0.77
The effect of ethanol on the metabolism of amphetamine by the rat. J Pharm Pharmacol (1969) 0.77
Human pharmacokinetic model for isophosphamide (NSC-1097241). Cancer Chemother Rep (1975) 0.77
The bioavailability in man of ICRF-159 a new oral antineoplastic agent. J Pharm Pharmacol (1975) 0.77
Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. Cancer Chemother Pharmacol (2000) 0.77
Analogs of amphetamine. 5. Studies of excretory metabolites of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats. J Med Chem (1971) 0.77
Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. Cancer Chemother Pharmacol (1997) 0.77
Renal clearance of camptothecin (NSC-100880): effect of urine volume. Cancer Chemother Rep (1973) 0.77
Neurochemical effects of L-tetra 9-tetrahydrocannabinol in rats following repeated inhalation. Brain Res (1971) 0.77
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. Cancer Invest (1999) 0.77
Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial. Cancer Epidemiol Biomarkers Prev (1993) 0.76
Inhibition of macromolecular biosynthesis in cultured L1210 mouse leukemia cells by thalicarpine (NSC 68075). Cancer Res (1973) 0.76
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724). Eur J Cancer (1976) 0.75
Methotrexate plasma decay kinetics: possible alteration in patients undergoing gut sterilization. Br J Cancer (1976) 0.75
Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma. Cancer Chemother Pharmacol (1989) 0.75
Binding of a new antitumor agent, thalicarpine, to DNA. J Pharm Sci (1974) 0.75
Clinical development of iproplatin (CHIP). Drugs Exp Clin Res (1986) 0.75
Phase I study of thalicarpine (NAC-68075), a plant alkaloid of noval structure. Cancer Chemother Rep (1976) 0.75
PTG, a new antineoplastic epipodyphyllotoxin. Clin Pharmacol Ther (1975) 0.75